Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled phase Ib/II clinical trial of MHB018A injection in subjects with moderate to severe thyroid-related eye disease

Next Previous
X
Search
Trial Profile

A randomized, double-blind, placebo-controlled phase Ib/II clinical trial of MHB018A injection in subjects with moderate to severe thyroid-related eye disease

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Oct 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MHB-018A (Primary)
  • Indications Graves ophthalmopathy
  • Focus Therapeutic Use
  • Sponsors Minghui Pharmaceutical (Shanghai)

    • Most Recent Events

    • 23 Oct 2024 New trial record
    • 22 Oct 2024 According to Minghui Pharmaceutical Inc Media Release, based on the results of this trial the company is planning to initiate Phase 3 registrational trials in the first half of 2025
    • 22 Oct 2024 According to Minghui Pharmaceutical Inc Media Release, Positive Topline Results from this trial

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top